Opinion|Videos|March 25, 2025
Academic Perspectives on Treatment Decisions for BPDCN
Author(s)Marlise R. Luskin, MD, MSCE
An expert discusses how, for younger/fitter patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), treatment selection as a bridge to transplant is based on efficacy, toxicity, and response depth. Patient-specific (age, comorbidities) and systemic (drug access, center expertise) factors guide decisions. Emerging real-world evidence, such as Berning et al (ASH 2024), highlights CD123-targeted therapy’s role in optimizing response rates before allogeneic stem cell transplantation (allo-SCT).
Advertisement
Video content above is prompted by the following:
- For patients with BPDCN who are younger/fitter, how do you determine which treatment options provide the greatest benefit as a bridge to transplant?
- What patient-specific and systemic/logistical factors influence your treatment choice?
- What are your thoughts on real-world evidence that evaluates response rates with CD123/consolidative allo-SCT in BPDCN (Berning et al, ASH 2024)?
Advertisement
Related to this article
The antibody-drug conjugate sofetabart mipitecan showed efficacy and safety, leading to selection of a phase 3 dose for the FRAmework-01 trial.
FDA grants orphan drug designation to onvansertib for relapsed or refractory CMML, boosting development of the PLK1 inhibitor after early signals of activity.
Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial.
New analysis reveals major gaps in US TNBC trial access, leaving rural and minority communities with fewer treatment options and research opportunities.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5